Galileo – Biotech Innovation Fund IM USD

Reference Data

ISIN LU2472219562
Valor Number
Bloomberg Global ID
Fund Name Galileo – Biotech Innovation Fund IM USD
Fund Provider IPConcept (Luxemburg) S.A. Zürich, Switzerland
Phone: +352 260248-1
E-Mail: info.lu@ipconcept.com
Web: www.ipconcept.com
Fund Provider IPConcept (Luxemburg) S.A.
Representative in Switzerland IPConcept (Schweiz) AG
Zürich
Phone: +41 044 224 32 09
Distributor(s) Bellecapital AG
Asset Class Equities
EFC Category
Distribution Policy Accumulation
Home Country Luxembourg
Issuing Condition The fund charges a transaction fee (contribution towards expenses incurred in the investment of new assets)
Redemption Condition The fund management company and/or distributor charges a redemption commission (different commissions can be charged for the same fund depending on the sales channel)
Investment Strategy *** The objective of the investment policy for the sub-fund is to achieve an appropriate level of growth in the sub-fund currency while taking the investment risk into account. The sub-fund is actively managed. The composition of the portfolio is determined by the Fund Manager solely in accordance with the criteria laid down in the investment objectives / the investment policy, is regularly reviewed and, if necessary, adjusted. The sub-fund is not managed using an index as a benchmark.
Peculiarities

Fund Prices

Current Price * 122.34 USD 28.11.2025
Previous Price * 122.24 USD 27.11.2025
52 Week High * 132.74 USD 16.10.2025
52 Week Low * 71.86 USD 09.04.2025
NAV * 122.34 USD 28.11.2025
Issue Price * 122.34 USD 28.11.2025
Redemption Price * 122.34 USD 28.11.2025
Closing Price *
Indicative Minimum Price
Fund Assets *** 42,048,250
Unit/Share Assets *** 506,539
Trading Information SIX

Performance

YTD Performance +19.95% 30.12.2024
28.11.2025
YTD Performance (in CHF) +6.52% 30.12.2024
28.11.2025
1 month -6.12% 28.10.2025
28.11.2025
3 months +25.07% 28.08.2025
28.11.2025
6 months +49.74% 28.05.2025
28.11.2025
1 year +3.49% 28.11.2024
28.11.2025
2 years +9.76% 28.11.2023
28.11.2025
3 years -21.74% 28.11.2022
28.11.2025
5 years -18.44% 31.05.2022
28.11.2025

Tax Data

Equity Participation Rate in %
Share of Total Fund Assets in %
Real Estate Rate in %
ADDI
ADDI Date

Top 10 Holdings ***

Krystal Biotech Inc 8.74%
Arcellx Inc 8.63%
Vertex Pharmaceuticals Inc 5.91%
Alnylam Pharmaceuticals Inc 5.75%
BioNTech SE ADR 4.80%
Regeneron Pharmaceuticals Inc 3.82%
Stoke Therapeutics Inc 3.67%
Gilead Sciences Inc 3.11%
AbbVie Inc 2.88%
Bristol-Myers Squibb Co 2.75%
Last data update 30.04.2025

Cost / Risk

TER
TER date
Performance Fee ***
PTR
Max. Management Fee *** 1.25%
Ongoing Charges *** 1.71%
SRRI ***
SRRI date *** 31.10.2025

Breakdowns

Equity Countries ***

Equity Sectors ***

Bond Sectors ***


* NAV / Issue Price exclusive commissions, for listed funds NAV or closing price
** Calculation of interim profit followed § 9 Satz 2 InvStG
*** Data source: Morningstar (Data is based on the rescaled long position of the holdings)